Skip to main content

Articles

Page 2 of 25

  1. The entry of artificial intelligence into medicine is pending. Several methods have been used for the predictions of structured neuroimaging data, yet nobody compared them in this context.

    Authors: Leonie Lampe, Sebastian Niehaus, Hans-Jürgen Huppertz, Alberto Merola, Janis Reinelt, Karsten Mueller, Sarah Anderl-Straub, Klaus Fassbender, Klaus Fliessbach, Holger Jahn, Johannes Kornhuber, Martin Lauer, Johannes Prudlo, Anja Schneider, Matthis Synofzik, Adrian Danek…
    Citation: Alzheimer's Research & Therapy 2022 14:62
  2. Cerebrospinal fluid (CSF) lactate levels have been suggested to be associated with disease severity and progression in several neurological diseases as an indicator of impaired energy metabolism, neuronal deat...

    Authors: Paul Theo Zebhauser, Achim Berthele, Oliver Goldhardt, Janine Diehl-Schmid, Josef Priller, Marion Ortner and Timo Grimmer
    Citation: Alzheimer's Research & Therapy 2022 14:61
  3. Cerebrospinal fluid (CSF) analysis for detecting amyloid positivity may be as reliable as positron emission tomography (PET). We evaluated the performance of the amyloid beta (Aβ)42/40 ratio for predicting amy...

    Authors: Michaela Amft, Marion Ortner, Udo Eichenlaub, Oliver Goldhardt, Janine Diehl-Schmid, Dennis M. Hedderich, Igor Yakushev and Timo Grimmer
    Citation: Alzheimer's Research & Therapy 2022 14:60
  4. Slowed clearance of amyloid β (Aβ) is believed to underlie the development of Aβ plaques that characterize Alzheimer’s disease (AD). Aβ is cleared in part by the glymphatic system, a brain-wide network of peri...

    Authors: Matthew Simon, Marie Xun Wang, Ozama Ismail, Molly Braun, Abigail G. Schindler, Jesica Reemmer, Zhongya Wang, Mariya A. Haveliwala, Ryan P. O’Boyle, Warren Y. Han, Natalie Roese, Marjorie Grafe, Randall Woltjer, Detlev Boison and Jeffrey J. Iliff
    Citation: Alzheimer's Research & Therapy 2022 14:59
  5. There is currently a lack of reliable and easily accessible biomarkers predicting cognitive decline in Alzheimer’s disease (AD). Synaptic dysfunction and loss occur early in AD and synaptic loss measured in th...

    Authors: Pia Kivisäkk, Becky C. Carlyle, Thadryan Sweeney, James P. Quinn, Christopher E. Ramirez, Bianca A. Trombetta, Muriel Mendes, Mary Brock, Carrie Rubel, Julie Czerkowicz, Danielle Graham and Steven E. Arnold
    Citation: Alzheimer's Research & Therapy 2022 14:58
  6. To evaluate a wide range of optical coherence tomography (OCT) parameters for possible application as a screening tool for cognitively healthy individuals at risk of Alzheimer’s disease (AD), assessing the pot...

    Authors: Alicia López-de-Eguileta, Sara López-García, Carmen Lage, Ana Pozueta, María García-Martínez, Martha Kazimierczak, María Bravo, Juan Irure, Marcos López-Hoyos, Pedro Muñoz-Cacho, Noelia Rodríguez-Perez, Diana Tordesillas-Gutiérrez, Alexander Goikoetxea, Claudia Nebot, Eloy Rodríguez-Rodríguez, Alfonso Casado…
    Citation: Alzheimer's Research & Therapy 2022 14:57
  7. Alzheimer’s disease is the most prevalent cause of dementia in the elderly. Neuronal death and synaptic dysfunctions are considered the main hallmarks of this disease. The latter could be directly associated t...

    Authors: Andrea González, Camila Calfío, Macarena Churruca and Ricardo B. Maccioni
    Citation: Alzheimer's Research & Therapy 2022 14:56
  8. Previous models of Alzheimer’s disease (AD) progression were primarily hypothetical or based on data originating from single cohort studies. However, cohort datasets are subject to specific inclusion and exclu...

    Authors: Sepehr Golriz Khatami, Yasamin Salimi, Martin Hofmann-Apitius, Neil P. Oxtoby and Colin Birkenbihl
    Citation: Alzheimer's Research & Therapy 2022 14:55
  9. The need for preventive therapies that interrupt the progression of Alzheimer’s disease (AD) before the onset of symptoms or when symptoms are emerging is urgent and has spurred the ongoing development of dise...

    Authors: Sheila Seleri Assunção, Reisa A. Sperling, Craig Ritchie, Diana R. Kerwin, Paul S. Aisen, Claire Lansdall, Alireza Atri and Jeffrey Cummings
    Citation: Alzheimer's Research & Therapy 2022 14:54
  10. The degeneration of the cholinergic circuit from the basal forebrain to the hippocampus contributes to memory loss in patients suffering from Alzheimer’s disease (AD). However, the internal relationships betwe...

    Authors: Weilin Liu, Jianhong Li, Minguang Yang, Xiaohua Ke, Yaling Dai, Huawei Lin, Sinuo Wang, Lidian Chen and Jing Tao
    Citation: Alzheimer's Research & Therapy 2022 14:53
  11. Studies exploring topological properties of the metabolic network during the presymptomatic stage of genetic frontotemporal dementia (FTD) are scarce. However, such knowledge is important for understanding bra...

    Authors: Li Liu, Min Chu, Binbin Nie, Lin Liu, Kexin Xie, Yue Cui, Yu Kong, Zhongyun Chen, Haitian Nan, Kewei Chen, Pedro Rosa-Neto and Liyong Wu
    Citation: Alzheimer's Research & Therapy 2022 14:52
  12. Tau deposition in the mesial temporal lobe (MTL) in the absence of amyloid-β (Aβ−) occurs with aging. The tau PET tracer 18F-MK6240 has low non-specific background binding so is well suited to exploration of earl...

    Authors: Natasha Krishnadas, Vincent Doré, Colin Groot, Fiona Lamb, Pierrick Bourgeat, Samantha C. Burnham, Kun Huang, Anita M. Y. Goh, Colin L. Masters, Victor L. Villemagne and Christopher C. Rowe
    Citation: Alzheimer's Research & Therapy 2022 14:51
  13. The ability to understand emotions is often disturbed in patients with cognitive impairments. Right temporal lobe structures play a crucial role in emotional processing, especially the amygdala, temporal pole ...

    Authors: Jana Amlerova, Jan Laczó, Zuzana Nedelska, Martina Laczó, Martin Vyhnálek, Bing Zhang, Kateřina Sheardova, Francesco Angelucci, Ross Andel and Jakub Hort
    Citation: Alzheimer's Research & Therapy 2022 14:50
  14. Tau positron emission tomography (PET) is increasing in popularity for biomarker characterization of Alzheimer’s disease (AD), and recent frameworks rely on tau PET cut-points to stage individuals along the AD...

    Authors: Alexandra J. Weigand, Anne Maass, Graham L. Eglit and Mark W. Bondi
    Citation: Alzheimer's Research & Therapy 2022 14:49
  15. Neuropsychiatric symptoms (NPS) are common in individuals with Alzheimer’s disease (AD) dementia, but substantial heterogeneity exists in the manifestation of NPS. Sex differences may explain this clinical var...

    Authors: Willem S. Eikelboom, Michel Pan, Rik Ossenkoppele, Michiel Coesmans, Jennifer R. Gatchel, Zahinoor Ismail, Krista L. Lanctôt, Corinne E. Fischer, Moyra E. Mortby, Esther van den Berg and Janne M. Papma
    Citation: Alzheimer's Research & Therapy 2022 14:48
  16. Apolipoprotein E epsilon 4 (APOE-ε4) carrier status is an established risk factor for Alzheimer’s disease (AD) dementia. It has also been linked with sleep disturbance in healthy older adults and increased insomn...

    Authors: Jonathan Blackman, Seth Love, Lindsey Sinclair, Richard Cain and Elizabeth Coulthard
    Citation: Alzheimer's Research & Therapy 2022 14:47
  17. Up to now, there are no clinically available minimally invasive biomarkers to accurately identify mild cognitive impairment (MCI) patients who are at greater risk to progress to Alzheimer’s disease (AD) dement...

    Authors: Alexa Pichet Binette, Sebastian Palmqvist, Divya Bali, Gill Farrar, Christopher J. Buckley, David A. Wolk, Henrik Zetterberg, Kaj Blennow, Shorena Janelidze and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2022 14:46
  18. FACEmemory® is the first computerized, self-administered verbal episodic memory test with voice recognition. It can be conducted under minimal supervision and contains an automatic scoring system to avoid admi...

    Authors: Montserrat Alegret, Oscar Sotolongo-Grau, Ester Esteban de Antonio, Alba Pérez-Cordón, Adelina Orellana, Ana Espinosa, Silvia Gil, Daniel Jiménez, Gemma Ortega, Angela Sanabria, Natalia Roberto, Isabel Hernández, Maitee Rosende-Roca, Juan Pablo Tartari, Emilio Alarcon-Martin, Itziar de Rojas…
    Citation: Alzheimer's Research & Therapy 2022 14:43
  19. Authors: Panchanan Maiti, Zackary Bowers, Ali Bourcier-Schultz, Jarod Morse and Gary L. Dunbar
    Citation: Alzheimer's Research & Therapy 2022 14:42

    The original article was published in Alzheimer's Research & Therapy 2021 13:37

  20. Diagnostic performance of optical coherence tomography (OCT) to detect Alzheimer’s disease (AD) and mild cognitive impairment (MCI) remains limited. We assessed whether compensating the circumpapillary retinal...

    Authors: Jacqueline Chua, Chi Li, Lucius Kang Hua Ho, Damon Wong, Bingyao Tan, Xinwen Yao, Alfred Gan, Florian Schwarzhans, Gerhard Garhöfer, Chelvin C. A. Sng, Saima Hilal, Narayanaswamy Venketasubramanian, Carol Y. Cheung, Georg Fischer, Clemens Vass, Tien Yin Wong…
    Citation: Alzheimer's Research & Therapy 2022 14:41
  21. Temporary disruption of the blood-brain barrier (BBB) using pulsed ultrasound leads to the clearance of both amyloid and tau from the brain, increased neurogenesis, and mitigation of cognitive decline in pre-c...

    Authors: Stéphane Epelbaum, Ninon Burgos, Michael Canney, Dawn Matthews, Marion Houot, Mathieu D. Santin, Carole Desseaux, Guillaume Bouchoux, Sebastian Stroer, Cyril Martin, Marie-Odile Habert, Marcel Levy, Aicha Bah, Karine Martin, Benoît Delatour, Maximilien Riche…
    Citation: Alzheimer's Research & Therapy 2022 14:40
  22. Basic studies suggest that olfactory dysfunction and functional near-infrared spectroscopy (fNIRS) can be used as tools for the diagnosis of mild cognitive impairment (MCI); however, real-world evidence is lac...

    Authors: Jaewon Kim, Dong Keon Yon, Kyu Yeong Choi, Jang Jae Lee, Namwoo Kim, Kun Ho Lee and Jae Gwan Kim
    Citation: Alzheimer's Research & Therapy 2022 14:39
  23. Analysis of functional brain networks in Alzheimer’s disease (AD) has been hampered by a lack of reproducible, yet valid metrics of functional connectivity (FC). This study aimed to assess both the sensitivity...

    Authors: Deborah N. Schoonhoven, Casper T. Briels, Arjan Hillebrand, Philip Scheltens, Cornelis J. Stam and Alida A. Gouw
    Citation: Alzheimer's Research & Therapy 2022 14:38
  24. Thioredoxin-80 (Trx80) is a cleavage product from the redox-active protein Thioredoxin-1 and has been previously described as a pro-inflammatory cytokine secreted by immune cells. Previous studies in our group...

    Authors: Julen Goikolea, Gorka Gerenu, Makrina Daniilidou, Francesca Mangialasche, Patrizia Mecocci, Tiia Ngandu, Juha Rinne, Alina Solomon, Miia Kivipelto, Angel Cedazo-Minguez, Anna Sandebring-Matton and Silvia Maioli
    Citation: Alzheimer's Research & Therapy 2022 14:37
  25. An aging society has increased rates of late onset Alzheimer disease dementia (ADD), the most common form of age-related dementia. This neurodegenerative disease disproportionately affects women.

    Authors: Filippo Cieri, Xiaowei Zhuang, Dietmar Cordes, Nikki Kaplan, Jeffery Cummings and Jessica Caldwell
    Citation: Alzheimer's Research & Therapy 2022 14:36
  26. Plasma amyloid-β (Aβ) may facilitate identification of individuals with brain amyloidosis. Gut microbial dysbiosis in Alzheimer’s disease (AD) is increasingly being recognized. However, knowledge about alterat...

    Authors: Can Sheng, Kun Yang, Beiqi He, Wenying Du, Yanning Cai and Ying Han
    Citation: Alzheimer's Research & Therapy 2022 14:35
  27. Alzheimer’s disease (AD) substantially increases health-related costs. This study investigates direct medical costs and characterizes the caregiver burden across AD stages.

    Authors: Virginie Dauphinot, Michele Potashman, Mihaela Levitchi-Benea, Ray Su, Ivana Rubino and Pierre Krolak-Salmon
    Citation: Alzheimer's Research & Therapy 2022 14:34
  28. Positron emission tomography (PET) with amyloid tracers (amy-PET) allows the quantification of pathological amyloid deposition in the brain tissues, including the white matter (WM). Here, we evaluate amy-PET u...

    Authors: Anna M. Pietroboni, Annalisa Colombi, Tiziana Carandini, Luca Sacchi, Chiara Fenoglio, Giorgio Marotta, Andrea Arighi, Milena A. De Riz, Giorgio G. Fumagalli, Massimo Castellani, Marco Bozzali, Elio Scarpini and Daniela Galimberti
    Citation: Alzheimer's Research & Therapy 2022 14:33
  29. Intracranial internal carotid artery (ICA) calcification is a common incidental finding in non-contrast head CT. We evaluated the predictive value of ICAC (ICAC) for future risk of cognitive decline and compar...

    Authors: Farzaneh Rahmani, Marina Nguyen, Charles D. Chen, Nicole McKay, Aylin Dincer, Nelly Joseph-Mathurin, Gengsheng Chen, Jingxia Liu, Hilary L. P. Orlowski, John C. Morris and Tammie L. S. Benzinger
    Citation: Alzheimer's Research & Therapy 2022 14:32
  30. The NIA-AA research framework proposes a purely biological definition of Alzheimer’s disease (AD). This implies that AD can be diagnosed based on biomarker abnormalities, irrespective of clinical manifestation...

    Authors: Jetske van der Schaar, Leonie N. C. Visser, Femke H. Bouwman, Johannes C. F. Ket, Philip Scheltens, Annelien L. Bredenoord and Wiesje M. van der Flier
    Citation: Alzheimer's Research & Therapy 2022 14:31
  31. While Alzheimer disease (AD) is generally considered as a brain disorder, blood biomarkers may be useful for the diagnosis and prediction of AD brain pathology. The APOE ε4 allele has shown cerebrovascular effect...

    Authors: Rebecca Panitch, Junming Hu, Weiming Xia, David A. Bennett, Thor D. Stein, Lindsay A. Farrer and Gyungah R. Jun
    Citation: Alzheimer's Research & Therapy 2022 14:30
  32. Cerebrospinal fluid (CSF) tau and beta-amyloid levels in chronic traumatic encephalopathy (CTE), a disease which can be clinically indistinguishable from Alzheimer’s disease (AD), are largely unknown. We exami...

    Authors: Katherine W. Turk, Alexandra Geada, Victor E. Alvarez, Weiming Xia, Jonathan D. Cherry, Raymond Nicks, Gaoyuan Meng, Sarah Daley, Yorghos Tripodis, Bertrand R. Huber, Andrew E. Budson, Brigid Dwyer, Neil W. Kowall, Robert C. Cantu, Lee E. Goldstein, Douglas I. Katz…
    Citation: Alzheimer's Research & Therapy 2022 14:28
  33. Cortical mean diffusivity is a novel imaging metric sensitive to early changes in neurodegenerative syndromes. Higher cortical mean diffusivity values reflect microstructural disorganization and have been prop...

    Authors: Ignacio Illán-Gala, Victor Montal, Sergi Borrego-Écija, Maria Luisa Mandelli, Neus Falgàs, Ariane E. Welch, Jordi Pegueroles, Miguel Santos-Santos, Alexandre Bejanin, Daniel Alcolea, Oriol Dols-Icardo, Olivia Belbin, Mª. Belén Sánchez-Saudinós, Nuria Bargalló, Sofía González-Ortiz, Albert Lladó…
    Citation: Alzheimer's Research & Therapy 2022 14:27
  34. Plasma biomarkers for Alzheimer’s disease (AD) have broad potential as screening tools in primary care and disease-modifying trials. Detecting elevated amyloid-β (Aβ) pathology to support trial recruitment or ...

    Authors: Andréa L. Benedet, Wagner S. Brum, Oskar Hansson, Thomas K. Karikari, Eduardo R. Zimmer, Henrik Zetterberg, Kaj Blennow and Nicholas J. Ashton
    Citation: Alzheimer's Research & Therapy 2022 14:26
  35. Cholinergic neurotransmitter system dysfunction contributes to cognitive impairment in Alzheimer’s disease and other syndromes. However, the specific cholinergic mechanisms and brain structures involved, time ...

    Authors: David L. Sultzer, Aaron C. Lim, Hailey L. Gordon, Brandon C. Yarns and Rebecca J. Melrose
    Citation: Alzheimer's Research & Therapy 2022 14:25
  36. Increasing evidence implicates oxidative stress (OS) in Alzheimer disease (AD) and mild cognitive impairment (MCI). Depletion of the brain antioxidant glutathione (GSH) may be important in OS-mediated neurodeg...

    Authors: Jinghan Jenny Chen, Mathura Thiyagarajah, Jianmeng Song, Clara Chen, Nathan Herrmann, Damien Gallagher, Mark J. Rapoport, Sandra E. Black, Joel Ramirez, Ana C. Andreazza, Paul Oh, Susan Marzolini, Simon J. Graham and Krista L. Lanctôt
    Citation: Alzheimer's Research & Therapy 2022 14:23
  37. Genetic variants within the APOE locus may modulate Alzheimer’s disease (AD) risk independently or in conjunction with APOE*2/3/4 genotypes. Identifying such variants and mechanisms would importantly advance our ...

    Authors: Michael E. Belloy, Sarah J. Eger, Yann Le Guen, Vincent Damotte, Shahzad Ahmad, M. Arfan Ikram, Alfredo Ramirez, Anthoula C. Tsolaki, Giacomina Rossi, Iris E. Jansen, Itziar de Rojas, Kayenat Parveen, Kristel Sleegers, Martin Ingelsson, Mikko Hiltunen, Najaf Amin…
    Citation: Alzheimer's Research & Therapy 2022 14:22
  38. To evaluate the diagnostic value of plasma β-amyloid (Aβ) seeding activity measured using a newly developed instrument to distinguish Alzheimer’s disease (AD) from other forms of dementia.

    Authors: Jianping Jia, Tingting Li, Jianwei Yang, Baian Chen, Wei Qin, Cuibai Wei, Yang Song, Qigeng Wang, Yan Li and Longfei Jia
    Citation: Alzheimer's Research & Therapy 2022 14:21
  39. Cerebrospinal fluid (CSF) Aβ1–42 levels and the Aβ1–42/Aβ1–40 ratio are markers of amyloid pathology, but previous studies suggest that their levels might be influenced by additional pathophysiological processes.

    Authors: Constance Delaby, Teresa Estellés, Nuole Zhu, Javier Arranz, Isabel Barroeta, María Carmona-Iragui, Ignacio Illán-Gala, Miguel Ángel Santos-Santos, Miren Altuna, Isabel Sala, M. Belén Sánchez-Saudinós, Laura Videla, Sílvia Valldeneu, Andrea Subirana, Mireia Tondo, Francisco Blanco-Vaca…
    Citation: Alzheimer's Research & Therapy 2022 14:20
  40. Gangliosides are highly enriched in the brain and are critical for its normal development and function. However, in some rare neurometabolic diseases, a deficiency in lysosomal ganglioside hydrolysis is pathog...

    Authors: James C. Dodge, Thomas J. Tamsett, Christopher M. Treleaven, Tatyana V. Taksir, Peter Piepenhagen, S. Pablo Sardi, Seng H. Cheng and Lamya S. Shihabuddin
    Citation: Alzheimer's Research & Therapy 2022 14:19
  41. Expanding technologies of early detection of Alzheimer’s disease allow to identify individuals at risk of dementia in early and asymptomatic disease stages. Neuropsychiatric symptoms, such as anxiety and depre...

    Authors: Ayda Rostamzadeh, Anna Kahlert, Franziska Kalthegener and Frank Jessen
    Citation: Alzheimer's Research & Therapy 2022 14:18

    The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:44

  42. Until now, Mendelian randomization (MR) studies have investigated the causal association of risk factors with Alzheimer’s disease (AD) using large-scale AD genome-wide association studies (GWAS), GWAS by proxy...

    Authors: Haijie Liu, Yang Hu, Yan Zhang, Haihua Zhang, Shan Gao, Longcai Wang, Tao Wang, Zhifa Han, Bao-liang Sun and Guiyou Liu
    Citation: Alzheimer's Research & Therapy 2022 14:17
  43. The progression rates of Alzheimer’s disease (AD) are variable and dynamic, yet the mechanisms that contribute to heterogeneity in progression rates remain ill-understood. Particularly, the role of synergies i...

    Authors: Muhammad Usman Sadiq, Kichang Kwak and Eran Dayan
    Citation: Alzheimer's Research & Therapy 2022 14:16
  44. Alzheimer’s disease (AD), the most common form of dementia, is a progressive neurodegenerative disorder that mainly affects older adults. One of the pathological hallmarks of AD is abnormally aggregated Tau pr...

    Authors: Isabelle Aillaud, Senthilvelrajan Kaniyappan, Ram Reddy Chandupatla, Lisa Marie Ramirez, Sewar Alkhashrom, Jutta Eichler, Anselm H. C. Horn, Markus Zweckstetter, Eckhard Mandelkow, Heinrich Sticht and Susanne Aileen Funke
    Citation: Alzheimer's Research & Therapy 2022 14:15
  45. Dementia with Lewy bodies (DLB) includes various core clinical features that result in different phenotypes. In addition, Alzheimer’s disease (AD) and cerebrovascular pathologies are common in DLB. All this in...

    Authors: Carla Abdelnour, Daniel Ferreira, Marleen van de Beek, Nira Cedres, Ketil Oppedal, Lena Cavallin, Frédéric Blanc, Olivier Bousiges, Lars-Olof Wahlund, Andrea Pilotto, Alessandro Padovani, Mercè Boada, Javier Pagonabarraga, Jaime Kulisevsky, Dag Aarsland, Afina W. Lemstra…
    Citation: Alzheimer's Research & Therapy 2022 14:14
  46. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Jun Pyo Kim, Bo-Hyun Kim, Paula J. Bice, Sang Won Seo, David A. Bennett, Andrew J. Saykin and Kwangsik Nho
    Citation: Alzheimer's Research & Therapy 2022 14:13

    The original article was published in Alzheimer's Research & Therapy 2021 13:164